Apelin-13

CAT:
804-HY-P1944
Size:
1 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Apelin-13 - image 1

Apelin-13

  • UNSPSC Description:

    Apelin-13 is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 is widely distributed in the central and peripheral nervous systems. Apelin-13 has vasodilatory and antihypertensive effects. Apelin-13 also can be used for researching type 2 diabetes and metabolic syndrome[1][2][3].
  • Target Antigen:

    Apelin Receptor (APJ)
  • Type:

    Peptides
  • Related Pathways:

    GPCR/G Protein
  • Applications:

    Metabolism-protein/nucleotide metabolism
  • Field of Research:

    Metabolic Disease; Cardiovascular Disease
  • Assay Protocol:

    https://www.medchemexpress.com/apelin-13.html
  • Solubility:

    10 mM in DMSO
  • Smiles:

    O=C(O)[C@H](CC1=CC=CC=C1)NC([C@H]2N(C([C@H](CCSC)NC([C@H]3N(C(CNC([C@H](CCCCN)NC([C@H](CC4=CNC=N4)NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CCCNC(N)=N)NC([C@H]5N(C([C@H](CCCNC(N)=N)NC([C@H](CCC(N)=O)N)=O)=O)CCC5)=O)=O)=O)=O)=O)=O)=O)CCC3)=O)=O)CCC2)=O
  • Molecular Weight:

    1550.83
  • References & Citations:

    [1]Tatemoto, K., Hosoya, M., Habata, Y., et al. Isolation and characterizaton of a novel endogenous peptide ligand for the human APJ receptor. Biochemical and Biophysical Research Communications 251, 471-476 (1998).|[2]Li M,et al. Apelin 13 ameliorates metabolic and cardiovascular disorders in a rat model of type 2 diabetes with a high fat diet. Mol Med Rep. 2018 Dec;18(6):5784-5790.|[3]Yamaleyeva LM, et al. Apelin-13 in blood pressure regulation and cardiovascular disease. Curr Opin Nephrol Hypertens. 2016 Sep;25(5):396-403.|[4]Wang Y, et al. Apelin-13 regulates electrical activity in the globus pallidus and induces postural changes in rats. Neural Regen Res. 2021 Nov;16(11):2264-2268.Ann Transl Med. 2021 Apr;9(8):627.|Biochim Biophys Acta Mol Basis Dis. 2024 Mar 19;1870(4):167125.|Microsc Res Tech. 2024 Feb 21.|Signal Transduct Target Ther. 2021 Dec 16;6(1):427.|Int J Nanomedicine. 2024 Sep 7:19:9175-9193.|Stem Cells Int. 2022 Mar 21;2022:3742678.
  • Shipping Conditions:

    Room temperature
  • Clinical Information:

    Phase 1
  • CAS Number:

    217082-58-1